Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NYMOX PHARMACEUTICAL CORPORATION

(NYMX)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000 Index

06/25/2021 | 12:00am EDT

Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000 Index


ę S&P Capital IQ 2021
All news about NYMOX PHARMACEUTICAL CORPORATION
09/20NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from S&P Global BMI Index
CI
09/10NYMOX PHARMACEUTICAL : Files for Regulatory Approval of Fexapotide Triflutate Brand Names
MT
09/10NYMOX PHARMACEUTICAL : Provides Shareholder Update
AQ
08/13NYMOX : Q2 Earnings Snapshot
AQ
08/13Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter Ended ..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell Small Cap Completeness I..
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000E Growth Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 2500 Growth Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000E Index
CI
06/25NYMOX PHARMACEUTICAL CORPORATION(NAS : NYMX) dropped from Russell 3000 Growth Index
CI
More news
Financials (USD)
Sales 2020 0,01 M - -
Net income 2020 -11,7 M - -
Net cash 2020 3,19 M - -
P/E ratio 2020 -15,6x
Yield 2020 -
Capitalization 171 M 171 M -
EV / Sales 2019 1 283x
EV / Sales 2020 37 731x
Nbr of Employees -
Free-Float 51,7%
Chart NYMOX PHARMACEUTICAL CORPORATION
Duration : Period :
Nymox Pharmaceutical Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NYMOX PHARMACEUTICAL CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Paul Averback Chairman, President & Chief Executive Officer
Erik Danielsen Chief Financial Officer
Randall J. Lanham COO, Secretary, Director & General Counsel
David S. Morse Independent Director
James G. Robinson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NYMOX PHARMACEUTICAL CORPORATION-17.74%171
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353